VILDAPRIDE D 100/10 TAB

About

VILDAPRIDE D 100/10 TAB is a combination medication for the treatment of type 2 diabetes mellitus, featuring Vildagliptin and Dapagliflozin. Vildagliptin, a DPP-4 inhibitor, enhances the body's own ability to control blood glucose by increasing active incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. Dapagliflozin, an SGLT2 inhibitor, reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine, thereby lowering blood glucose levels independently of insulin. This complementary action provides robust glycemic control, addresses multiple pathways of glucose dysregulation, and offers additional benefits such as potential weight loss and cardiovascular/renal protection.

Uses

• Treatment of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• When monotherapy or dual therapy is insufficient.
• To improve glycemic control and potentially reduce cardiovascular/renal risk.

Directions For Use

Take orally, typically once daily in the morning, with or without food. Adhere strictly to your physician's prescribed dosage.

Benefits

• Improved HbA1c levels.
• Dual mechanism of action for comprehensive control.
• Reduced fasting and post-prandial glucose.
• Potential for weight loss.
• Blood pressure reduction.
• Reduced risk of cardiovascular and renal events (Dapagliflozin).

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Thirst
• Dizziness
• Headache
• Nasopharyngitis
• Joint pain
• Skin rash
• Fatigue
• Ketoacidosis (rare)
• Dehydration
• Hypotension

Safety Measures

• Alcohol - Moderate alcohol intake is generally acceptable, but excessive consumption may increase risk of dehydration or ketoacidosis with SGLT2 inhibitors.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters. Consult a doctor immediately if pregnant.
• Breastfeeding - Not recommended as components may pass into breast milk. Consult a healthcare professional.
• Liver - Use with caution; Vildagliptin may require dose adjustment. Dapagliflozin generally does not require dose adjustment in mild-moderate impairment.
• Kidney - Dapagliflozin efficacy is reduced in severe renal impairment and not recommended for initiation below certain eGFR thresholds. Vildagliptin requires dose adjustment.
• Lung - No specific contraindications, but severe lung conditions might indirectly affect fluid balance, which should be monitored with SGLT2 inhibitors.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.